Corporate Banner
Satellite Banner
Stem Cells, Cellular Therapy & Biobanking
>
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Promega ViaFect™ Transfection Reagent Delivers High Performance Transfection Across Multiple Cell Lines, Including iPS Cells

Published: Tuesday, January 14, 2014
Last Updated: Tuesday, January 14, 2014
Bookmark and Share
Novel reagent formulation allows researchers to develop assays in more cell lines of interest

Promega Corporation announces ViaFect™ Transfection Reagent, a tool for efficient DNA transfer into a wide variety of cell lines, including challenging suspension cells and stem cell-derived lines. ViaFect Transfection Reagent allows researchers to develop transfection-based assays in the cell line most relevant for their biology of interest.

Induced pluripotent stem cell (iPSC)-derived cell models, such as Cellular Dynamics International's iCell® Cardiomyocytes, show robust transfection with ViaFect Transfection Reagent, enabling assays not possible with other reagents.

This low toxicity reagent allows cells to stay healthy and metabolically active during transfection-based experiments, even at low cell densities, facilitating experiments where extended application of a treatment is needed. Cell viabilities of greater than 90% are routinely observed following transfection with ViaFect Transfection Reagent.

ViaFect Transfection Reagent requires minimal optimization with a simple three-step protocol. It does not require removal of serum, removal of culture medium or washing after introduction of the reagent/DNA complex. ViaFect Transfection Reagent contains no animal-derived components. 

A poster detailing results using ViaFect Transfection Reagent will also be presented at the Society for Laboratory Automation and Screening Conference and Exhibition to be held January 18th-22nd in San Diego, CA.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
A Gene-Sequence Swap Using CRISPR to Cure Haemophilia
For the first time chromosomal defects responsible for hemophilia have been corrected in patient-specific iPSCs using CRISPR-Cas9 nucleases
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
New Material Forges the Way for 'Stem Cell Factories'
Researchers have discovered the first fully synthetic substrate with potential to grow billions of stem cells. The researchcould forge the way for the creation of 'stem cell factories' - the mass production of human embryonic (pluripotent) stem cells.
Liver Regrown from Stem Cells
Scientists have repaired a damaged liver in a mouse by transplanting stem cells grown in the laboratory.
Immunotherapy Shows Promise for Myeloma
A strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
'Google Maps' for the Body
Scientists have revealed research that uses previously top-secret technology to zoom through the human body down to the level of a single cell that could be a game-changer for medicine.
Adaptimmune's Novel Cancer Therapeutics Show Positive Clinical Trial Results
The company has announced that positive data from its Phase I/II study of its affinity enhanced T-cell receptor (TCR) therapeutic targeting the NY-ESO-1 cancer antigen in patients with multiple myeloma has been published.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!